대장암 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Colorectal Cancer Diagnostics Market size is expected to reach USD 35.98 Billion in 2034 from USD 20.14 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The global colorectal cancer diagnostics market is expanding due to the rising prevalence of colorectal cancer worldwide. Aging populations, sedentary lifestyles, and dietary changes have significantly increased the incidence rate, driving demand for early detection and screening solutions. Government initiatives promoting regular screenings and awareness campaigns are also contributing to market growth.

Technological advancements in molecular diagnostics, biomarker-based testing, and non-invasive screening methods such as fecal immunochemical tests are transforming the diagnostic landscape. Improved accuracy, faster turnaround times, and minimally invasive procedures are enhancing patient compliance. Additionally, integration of artificial intelligence in imaging and pathology is improving detection rates and reducing diagnostic errors.

Future prospects remain strong as precision medicine and personalized treatment approaches gain traction. Expansion of healthcare infrastructure in developing countries and growing investments in research and development will further accelerate market growth. Increasing adoption of home-based screening kits and digital health platforms is also expected to expand access and improve early diagnosis outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

• Blood Tests
• Stool Tests
• Imaging Tests (CT, Ultrasound, MRI, PET)
• Biopsy
• Other Test Types

By End Use

• Hospitals
• Diagnostic Imaging Centers
• Cancer Research Centers
• Other End Use

COMPANIES PROFILED

• Danaher Corporation, DiaCarta, Exact Sciences Corporation, F HoffmannLa Roche, GE HealthCare Technologies, Geneoscopy, Guardant Health, HU Group Holdings, New Day Diagnostics, Olympus Corporation, Phase Scientific International, QIAGEN NV, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Type
• 4.2. Blood Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Stool Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Imaging Tests (CT, Ultrasound, MRI, PET) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Test Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End Use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostic Imaging Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cancer Research Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other End Use Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Test Type
  • 6.2.2 By End Use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Test Type
  • 6.3.2 By End Use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Test Type
  • 6.4.2 By End Use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Test Type
  • 6.5.2 By End Use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Test Type
  • 6.6.2 By End Use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL COLORECTAL CANCER DIAGNOSTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Danaher Corporation
  • 8.2.2 DiaCarta
  • 8.2.3 Exact Sciences Corporation
  • 8.2.4 F. Hoffmann-La Roche
  • 8.2.5 GE HealthCare Technologies
  • 8.2.6 Geneoscopy
  • 8.2.7 Guardant Health
  • 8.2.8 H.U. Group Holdings
  • 8.2.9 New Day Diagnostics
  • 8.2.10 Olympus Corporation
  • 8.2.11 Phase Scientific International
  • 8.2.12 QIAGEN N.V
  • 8.2.13 Siemens Healthineers
  • 8.2.14 Sysmex Corporation
  • 8.2.15 Thermo Fisher Scientific